Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical NG, NG-dimethylarginine in human essential hypertension
Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical NG, NG-dimethylarginine in human essential hypertension
复制标题
DOI：
10.1016/s0895-7061(02)02278-1
复制
发表时间：
2002-07-01
影响因子：
3.2
通讯作者：
Schmieder, RE
中科院分区：
文献类型：
--
作者：
Delles, C;Schneider, MP;Schmieder, RE
背景：不对称的N - G，N - G - 二甲基精氨酸（ADMA）与人类内皮依赖性血管舒张功能受损有关。
方法：20名年轻男性轻度高血压患者被纳入一项随机、双盲、四重交叉研究。患者分别接受安慰剂、依那普利（20毫克/天）、依普罗沙坦（600毫克/天）或两种药物联合使用（分别为10毫克/天和300毫克/天），每种药物使用1周，之后是2周的洗脱期。在每个治疗阶段后，测量ADMA浓度。
结果：安慰剂阶段ADMA浓度为1.69 ± 0.59 μmol/L，在依那普利、依普罗沙坦和联合用药阶段显著降低（分别为1.41 ± 0.29、1.42 ± 0.43和1.38 ± 0.30 μmol/L，与安慰剂相比，均P < 0.05）。ADMA水平的变化与药物对血压（BP）的作用无关。
结论：依那普利和依普罗沙坦治疗可降低ADMA水平。我们的结果表明这些药物对ADMA水平有特定作用，且与血压无关。（C）2002年美国高血压杂志有限公司
Background: Asymmetrical N-G, N-G-dimethylarginine (ADMA) is associated with impaired endothelium-dependent vasodilation in humans.Methods: Twenty young, male. mildly hypertensive subjects were included in a randomized. double-blind, fourfold cross-over study with placebo, enalapril (20 mg/day), eprosartan (600 mg/day). or a combination of both drugs (10 and 300 mg/day. respectively) each over 1 week, followed by a 2-week wash-out phase. After each treatment phase, ADMA concentration was measured.Results: ADMA concentration was 1.69 +/- 0.59 mumol/L in the placebo phase, and was significantly lower in the enalapril. eprosartan. and combination phases (1.41 +/- 0.29, 1.42 +/- 0.43, and 1.38 +/- 0.30 mumol/L. respectively all P < 0.05 v placebo). Changes in ADMA levels were independent of the drugs' action on blood pressure (BP).Conclusions: Levels of ADMA were reduced with enalapril and eprosartan therapy. Our results suggest a specific action of these drugs on ADMA levels that is independent of BP. (C) 2002 American Journal of Hypertension, Ltd.